F. Hoffmann-La Roche Ltd: FDA approves Roche's Susvimo, a first-of-its-kind therapeutic approach for neovascular or wet age-related macular degeneration (nAMD)

Susvimo, previously called Port Delivery System with ranibizumab, is the first nAMD treatment in 15 years to provide an alternative to standard-of-care eye injections needed as often as once a monthBy

Related Keywords

Wills Eye Hospital ,Pennsylvania ,United States ,Japan ,Ireland ,Switzerland ,Philadelphia ,America ,Irish ,Nathalie Meetz ,Levi Garraway ,Jon Kaspar Bayard ,Karl Mahler ,Sabine Borngr ,Gerard Tobin ,Bruno Eschli ,Sileia Urech ,Birgit Masjost ,Loren Kalm ,Patrick Barth ,Carl Regillo ,Karsten Kleine ,Genentech ,Lancet Global Health ,Drug Administration ,Head Of Global Product Development ,Novartis ,Retina Service At Wills Eye Hospital ,European Medicines Agency ,Roche Group ,Pharmaceuticals Industry ,Roche Group Media Relations ,Port Delivery System ,Retina Service ,Chief Medical Officer ,Global Product ,World Health Organization Model Lists ,Essential Medicines ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Lancet Global ,Hoffmann ,Oche ,Pproves ,Usvimo ,First ,Wind ,Herapeutic ,Approach ,Neovascular ,Elated ,Macular ,Regeneration ,Amd ,